Back to top
more

Larimar Therapeutics (LRMR)

(Delayed Data from NSDQ)

$7.89 USD

7.89
3,011,096

+0.62 (8.53%)

Updated May 21, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat

by Zacks Equity Research

Nektar's (NKTR) Q1 loss is narrower than expected while revenues beat estimates.

Larimar (LRMR) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Larimar (LRMR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Theravance's (TBPH) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Thervance's (TBPH) first-quarter 2023 loss wider than expected. Revenues decline year over year and also miss estimates.

New Strong Buy Stocks for May 9th

by Zacks Equity Research

SBGI, AQST, PLTK, GTX and LRMR have been added to the Zacks Rank #1 (Strong Buy) List on May 9, 2023

United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss

by Zacks Equity Research

United Therapeutics' (UTHR) first-quarter 2023 earnings beat estimates while sales miss the same. Tyvaso sales continue to drive the company's top line.

Best Momentum Stocks to Buy for April 19th

by Zacks Equity Research

LRMR, VRTV and PLL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 19, 2023.

New Strong Buy Stocks for April 19th

by Zacks Equity Research

SIGA, RYI, LRMR, VRTV and PLL have been added to the Zacks Rank #1 (Strong Buy) List on April 19, 2023.

Here's Why You May Add Nektar (NKTR) Stock to Your Portfolio

by Zacks Equity Research

Here we discuss some reasons why investing in Nektar Therapeutics (NKTR) stock now is a good idea despite its several pipeline setbacks.

Here's Why You Should Invest in Larimar (LRMR) Stock Now

by Zacks Equity Research

Here we discuss some reasons why investing in Larimar Therapeutics (LRMR) stock now is a good idea.

Here's Why You Can Add KalVista (KALV) Stock to Your Portfolio

by Zacks Equity Research

Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now is a good idea.

New Strong Buy Stocks for April 12th

by Zacks Equity Research

CELU, MGI, LRMR, EQRX and SRZN have been added to the Zacks Rank #1 (Strong Buy) List on April 12, 2023.

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics

by Zacks Equity Research

Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics are part of the Zacks Industry Outlook article.

Kinjel Shah headshot

5 Stocks to Buy as the Drug Industry Rebounds in 2023

by Kinjel Shah

Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. CPRX, KALV, LRMR, NKTR, JNCE may prove to be good additions to one's portfolio.

Down -24.74% in 4 Weeks, Here's Why You Should You Buy the Dip in Larimar (LRMR)

by Zacks Equity Research

Larimar (LRMR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -29.33% in 4 Weeks, Here's Why You Should You Buy the Dip in Larimar (LRMR)

by Zacks Equity Research

Larimar (LRMR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -30% in 4 Weeks, Here's Why You Should You Buy the Dip in Larimar (LRMR)

by Zacks Equity Research

Larimar (LRMR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Industry Outlook Highlights Jazz Pharmaceuticals, Catalyst Pharmaceuticals, Aerie Pharmaceuticals, Larimar Therapeutics and Fusion Therapeutics

by Zacks Equity Research

Jazz Pharmaceuticals, Catalyst Pharmaceuticals, Aerie Pharmaceuticals, Larimar Therapeutics and Fusion Therapeutics have been highlighted in this Industry Outlook article.

Kinjel Shah headshot

5 Stocks to Bet on in an Innovation-Driven Drug Industry

by Kinjel Shah

Innovation is expected continue driving growth in the Medical-Drugs industry in 2023. JAZZ, CPRX, AERI, LRMR and FUSN may prove to be good additions to one's portfolio.

Best Momentum Stocks to Buy for October 7th

by Zacks Equity Research

MNTK, LRMR and TCOM made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 7, 2022.

New Strong Buy Stocks for October 7th

by Zacks Equity Research

PBR, HP, MNTK, LRMR and TCOM have been added to the Zacks Rank #1 (Strong Buy) List on October 7, 2022.

What Makes Larimar (LRMR) a New Buy Stock

by Zacks Equity Research

Larimar (LRMR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Down 21.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Larimar (LRMR)

by Zacks Equity Research

Larimar (LRMR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Catalyst (CPRX) Up More Than 20% in Past 3 Months: Here's Why

by Zacks Equity Research

Catalyst's (CPRX) lead drug, Firdapse, is approved for treating Lambert-Eaton myasthenic syndrome. The drug has seen solid uptake since its launch.

Catalyst (CPRX) Q2 Earnings Top Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Catalyst's (CPRX) earnings and revenues beat estimates in the second quarter of 2021. Shares inch up in after-hours trading.

Reata (RETA) Stock Down Despite Q2 Earnings & Sales Beat

by Zacks Equity Research

Reata (RETA) beats estimates for earnings and sales. Stock down on negative regulatory update on lead pipeline candidate, bardoxolone.